Evidence map›Paper›PMID 34426623›Full record

ArticleScientific reports2021

The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1

Amy Keerie, Heledd Brown-Wright, Isaac Kirkland, Andrew Grierson, James J P Alix, Christian Holscher, Richard J Mead

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  7. Review
  8. Associations Between Diabetes Mellitus and Neurodegenerative Diseases.International journal of molecular sciences · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Amy KeerieSheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.
Heledd Brown-WrightSheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.
Isaac KirklandSheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.
Andrew GriersonSheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.
James J P AlixSheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.
Christian HolscherSecond Hospital, Neurology Department, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Richard J MeadSheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK. r.j.mead@sheffield.ac.uk.
University of Sheffield · GBSecond Hospital of Shanxi Medical University · CN

Funding

Motor Neurone Disease Association SITRAN/APR13/983-797Motor Neurone Disease Association SITRAN/JUL16/987-797
6 · The paper itself

Abstract

GLP-1 receptor agonists used for the treatment of diabetes, have shown some neuroprotective effects in cellular and animal models of Alzheimer's disease (AD) and Parkinson's disease (PD). There are currently few studies investigating GLP-1 receptor agonists in the treatment of ALS, where these neuroprotective effects may be beneficial. Here we investigate the effects of liraglutide, a GLP-1 receptor agonist, in two well characterised transgenic mouse models of ALS (SOD1

Indexed as

Disease ProgressionGlucagon-Like Peptide-1 Receptor AgonistsAmyotrophic Lateral SclerosisAnimalsBehavior, AnimalBiomarkersBlood GlucoseCalcium-Binding ProteinsDisease Models, AnimalDNA-Binding ProteinsGlial Fibrillary Acidic ProteinGlucagon-Like Peptide-1 ReceptorLiraglutideLumbar VertebraeMiceMice, Inbred C57BLAif1 protein, mouseBiomarkersBlood GlucoseCalcium-Binding ProteinsDNA-Binding ProteinsGlial Fibrillary Acidic ProteinGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideMicrofilament ProteinsSuperoxide Dismutase-1Tardbp protein, mouse

Identifiers

PMID34426623
PMCPMC8382676
OpenAlexW3193716349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.